Hutchison China Meditech Limited Chi-Med Ph II gastric cancer data for Savolitinib
October 17 2019 - 1:26AM
RNS Non-Regulatory
TIDMHCM
Hutchison China Meditech Limited
17 October 2019
Press Release
Chi-Med highlights publication of Phase II data showing
promising efficacy for Savolitinib in MET-amplified gastric
cancers
London: Thursday, October 17, 2019: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) today highlighted the
publication of results from the Phase II VIKTORY (targeted agent
eValuation In gastric cancer basKeT KORea studY) trial in Cancer
Discovery, a journal of the American Association of Cancer
Research. The principal study investigator was Dr. Jeeyun Lee,
Associate Professor at the Division of Hematology-Oncology, Samsung
Medical Center, Sungkyunkwan University School of Medicine, Seoul,
Korea.
The research article titled "Tumor Genomic Profiling Guides
Patients with Metastatic Gastric Cancer to Targeted Treatment: The
VIKTORY Umbrella Trial" in the October 2019 issue of Cancer
Discovery details the VIKTORY study, which was designed to classify
patients with metastatic gastric cancer based on clinical
sequencing and focused on eight different biomarker groups,
including MET amplification, to assign patients to one of the 10
associated clinical trials in second-line treatment.
Dr. Lee and colleagues classified 772 patients with gastric
cancer and successfully sequenced 715 patients (92.6%). Based on
this sequencing, MET amplification was observed in 3.5% of patients
(25/715). Of the 10 associated clinical trials under the VIKTORY
umbrella, the highest objective response rate ("ORR") was observed
in the MET amplification savolitinib monotherapy trial, which
reported an ORR of 50% (10/20, 95% CI: 28.0 - 71.9). Dr. Lee and
colleagues concluded that the savolitinib monotherapy trial also
met the pre-specified 6-week progression free survival rate,
indicating that it is worthy of further exploration in the MET
amplification subset of patients with gastric cancer.
Gastric cancer was the third leading cause of cancer related
mortality in 2018, causing 783,000 deaths worldwide. The prognosis
of patients with metastatic gastric cancer remains extremely poor,
with a median overall survival of less than 12 months with
cytotoxic chemotherapy.
About Savolitinib
Savolitinib is a potential first-in-class inhibitor of MET, an
enzyme which has been shown to function abnormally in many types of
solid tumors. Chi-Med designed savolitinib to be a potent and
highly selective oral inhibitor, which, through chemical structure
modification, addresses human metabolite-related renal toxicity,
the primary issue that halted development of several other
selective MET inhibitors. In clinical studies to date, involving
over 900 patients, savolitinib has shown promising signs of
clinical efficacy in patients with MET gene alterations in multiple
tumor types with an acceptable safety profile. Chi-Med is currently
testing savolitinib in partnership with AstraZeneca in Phase Ib/II
studies, in multiple solid tumor indications, both as a monotherapy
and in combinations.
About Chi-Med
Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical
company which researches, develops, manufactures and markets
pharmaceutical products. Its Innovation Platform, Hutchison
MediPharma, has over 470 scientists and staff focusing on
discovering, developing and commercializing targeted therapeutics
and immunotherapies in oncology and autoimmune diseases. It has a
portfolio of eight cancer drug candidates currently in clinical
studies around the world. Chi-Med's Commercial Platform
manufactures, markets, and distributes prescription drugs and
consumer health products, covering an extensive network of
hospitals across China.
Chi-Med is headquartered in Hong Kong and is dual-listed on the
AIM market of the London Stock Exchange and the Nasdaq Global
Select Market. For more information, please visit:
www.chi-med.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements reflect Chi-Med's current expectations regarding future
events, including its expectations for the clinical development of
savolitinib, plans to initiate clinical studies for savolitinib,
its expectations as to whether such studies would meet their
primary or secondary endpoints, and its expectations as to the
timing of the completion and the release of results from such
studies. Forward-looking statements involve risks and
uncertainties. Such risks and uncertainties include, among other
things, assumptions regarding enrollment rates, timing and
availability of subjects meeting a study's inclusion and exclusion
criteria, changes to clinical protocols or regulatory requirements,
unexpected adverse events or safety issues, the ability of drug
candidate savolitinib to meet the primary or secondary endpoint of
a study, to obtain regulatory approval in different jurisdictions
and to gain commercial acceptance after obtaining regulatory
approval, the potential market of savolitinib for a targeted
indication and the sufficiency of funding. In addition, as certain
studies rely on the use of Tagrisso(R) , Iressa(R) and Imfinzi(R)
as combination therapeutics with savolitinib, such risks and
uncertainties include assumptions regarding the safety, efficacy,
supply and continued regulatory approval of Tagrisso(R) , Iressa(R)
and Imfinzi(R) . Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. For further discussion of
these and other risks, see Chi-Med's filings with the U.S.
Securities and Exchange Commission and on AIM. Chi-Med undertakes
no obligation to update or revise the information contained in this
press release, whether as a result of new information, future
events or circumstances or otherwise.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile)
david.dible@citigatedewerogerson.com
Xuan Yang, Solebury Trout +1 (415) 971 9412 (Mobile)
xyang@troutgroup.com
Media Enquiries
UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Hong Kong & Asia ex-China - Joseph Chi Lo, Brunswick +852 9850 5033 (Mobile)
jlo@brunswickgroup.com
- Zhou Yi, Brunswick +852 9783 6894 (Mobile)
yzhou@brunswickgroup.com
Mainland China - Sam Shen, Edelman +86 136 7179 1029 (Mobile)
sam.shen@edelman.com
Nominated Advisor
Atholl Tweedie, Panmure Gordon (UK) Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEAKEXFALNFEF
(END) Dow Jones Newswires
October 17, 2019 02:26 ET (06:26 GMT)
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From Apr 2024 to May 2024
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From May 2023 to May 2024